Bergamaschi R, Capobianco M, Ravasio R. Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy. AboutOpen [Internet]. 2024 Jun. 17 [cited 2024 Jul. 3];11(1):48-56. Available from: https://journals.aboutscience.eu/index.php/aboutopen/article/view/3078